Brief: Proxalutamide Phase III Clinical Trial For The Treatment Of Covid-19 Patients Approved By FDA
05/03/2021 13:09
March 5 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* PROXALUTAMIDE PHASE III CLINICAL TRIAL FOR THE TREATMENT
OF
COVID-19 PATIENTS APPROVED BY FDA
Source text for Eikon: ID:nPn5jnSZMa
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint